Log In or Create Account

CROI
Conference on Bacteriophages
RWHAP CLINICAL CONFERENCE
Podcasts
Slides
Question of the Week
Guidelines
Contact

Advanced Search

CME Courses
CME Webinars
Dialogues
Topics In Antiviral Medicine
HIV Drug Resistance
Fellow Resources
About

Hyman Scott, MD, MPH

Hyman Scott, MD, MPH

Assistant Clinical Professor, School of Medicine

University of California San Francisco

San Francisco, CA

131 Steuart St, Suite 500, San Francisco, CA 94105

Phone: (415) 544-9400 | info@iasusa.org

Home
Activities
Resources
About
Contact
Login
Careers
Donate
Website Policies

© 2025 International Antiviral Society–USA. All Rights Reserved.

CROI
Conference on Bacteriophages
RWHAP CLINICAL CONFERENCE
Podcasts
Slides
Question of the Week
Guidelines
Contact
CME Courses
CME Webinars
Dialogues
Topics In Antiviral Medicine
HIV Drug Resistance
Fellow Resources
About

Practice Question of the Week

February 16, 2026: Recommended Laboratory Testing After Nonoccupational Postexposure Prophylaxis

Your patient initiated nonoccupational postexposure prophylaxis (nPEP) after a potential sexual exposure and recently completed her 28-day course of bictegravir (BIC)/tenofovir alafenamide (TAF)/emtricitabine (FTC). She started nPEP within 24 hours of exposure and reported no missed doses, and she reported no adverse events from the regimen. She is healthy and all baseline laboratory testing results were normal. Which of the following follow-up tests can be deferred?
- A. Week 4-6 alanine transaminase (ALT)/aspartate transaminase (AST) testing
- B. Week 4-6 HIV testing
- C. Week 12 ALT/AST testing
- D. Week 12 HIV testing

View the Presentation

View Archived Questions